Status:

COMPLETED

CHAMP: Study of NVK-002 in Children With Myopia

Lead Sponsor:

Vyluma, Inc.

Collaborating Sponsors:

Syneos Health

Conditions:

Myopia

Eligibility:

All Genders

3-17 years

Phase:

PHASE3

Brief Summary

Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. Stage 2: To...

Detailed Description

This will be a 3-arm randomized, multicenter, double-masked, placebo-controlled study conducted in 2 stages. Stage 1 is a safety and efficacy phase of 3 years in duration, during which subjects will ...

Eligibility Criteria

Inclusion

  • Children aged 3 to ≤ 17.0 years.
  • Myopia SER of at least -0.50 D and no worse than -6.00 D myopia in each eye as measured by cycloplegic autorefraction.

Exclusion

  • If present, astigmatism more than -1.50 D in either eye.
  • Current or history of amblyopia or strabismus.
  • History of any disease or syndrome that predisposes the subject to severe myopia (e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity).
  • History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, spherophakia).
  • Serious systemic illness that, in the Investigator's opinion, would render the subject ineligible.
  • Chronic use (more than 3 days per week) of any topical ophthalmic medications (prescribed or over the-counter) other than the assigned study medication.

Key Trial Info

Start Date :

November 20 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 19 2023

Estimated Enrollment :

670 Patients enrolled

Trial Details

Trial ID

NCT03350620

Start Date

November 20 2017

End Date

October 19 2023

Last Update

November 27 2024

Active Locations (26)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (26 locations)

1

Site #009

Tucson, Arizona, United States, 85711

2

Site #015

Berkeley, California, United States, 94720

3

Site #003

Fullerton, California, United States, 92831

4

Site #016

San Diego, California, United States, 92129

CHAMP: Study of NVK-002 in Children With Myopia | DecenTrialz